Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Orkin, Chloe; Arastéh, Keikawus; Górgolas Hernández-Mora, Miguel; Pokrovsky, Vadim; T. Overton, Edgar; Girard, Pierre‐Marie; Oka, Shinichi; Walmsley, Sharon; Bettacchi, Chris; Brinson, Cynthia; Philibert, Patrick; Lombaard, Johan; St. Clair, Marty; Crauwels, Herta; L. Ford, Susan; Patel, Parul; Chounta, Vasiliki; D’Amico, Ronald; Vanveggel, Simon; Dorey, David; Cutrell, Amy; Griffith, Sandy; A. Margolis, David; Williams, Peter; Parys, Wim; Y. Smith, Kimberly; Spreen, William

doi:10.1056/nejmoa1909512

Public

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Published in New England Journal of Medicine • Mar 4, 2020

Authors:

Chloe Orkin

Keikawus Arastéh

Miguel Górgolas Hernández-Mora

Abstract

BACKGROUND: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were giv...

Subject

Rilpivirine

Human immunodeficiency virus (HIV)

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!